PROSTVAC-V/F

BIOLOGICAL2 trials

Sponsors

Medical University of South Carolina, National Cancer Institute (NCI)

Conditions

Prostate CancerProstatic Neoplasms

Phase 1

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

CompletedNCT02933255

National Cancer Institute (NCI)Prostate Cancer

Start: 2017-04-18End: 2023-12-01Updated: 2024-05-31

Phase 2

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

TerminatedNCT02772562

Medical University of South CarolinaProstatic Neoplasms

Start: 2016-07-18End: 2024-04-29Updated: 2025-12-12

Related Papers

Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer

Journal for ImmunoTherapy of Cancer2025-06-014 citations

420 PROSTVAC in combination with nivolumab enhanced immune cell infiltration in prostate cancer

Regular and Young Investigator Award Abstracts2021-11-013 citations

Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.

2017-05-1214 citations